This study will be an open, non-randomised, clinical phase 2 trial, which will involve 30
women diagnosed with uterine papillary serous cancer. The researchers will investigate the
effect of four cycles of paclitaxel/carboplatin, followed by whole pelvic external beam
radiotherapy to a standard pelvis field (50.4 Gy) with or without a para-aortic boost with
respect to the safety and efficacy of treatment, and patterns of recurrence.
The purpose of this study is to examine the effectiveness of Misoprostol (Cytotec; GD Searle
and Co., Chicago, IL) for the management of non-viable first trimester pregnancies.
Specifically, Misoprostol (15-S-15-methyl PGE1) will be compared to a placebo with expectant
management in who have documented non-viable gestations. We will examine the following
outcome variables: time to resolution, number of patients requiring dilation and curettage,
change in hematocrit, cost to the institution, patient satisfaction, and reported side
effects.
We are doing this study to find out if extra medicine is needed to avoid the chance of nausea
sometimes linked to narcotic pain medicine (for example, morphine, dilaudid, fentanyl). Some
doctors always give medicine to prevent the possible side effect of nausea, while others do
not. We are looking to see if this extra medicine is helpful in preventing nausea. The goal
is to screen all patients with pain and enroll enough subjects to reach our goal of 164
evaluable study participants.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
